immunotherapies

Research in Review
Trastuzumab Cost Effectiveness Varies Based on Hormone Receptor Status
09/06/2016
JCP Editors
How cost effective trastuzumab is for human epidermal growth factor receptor 2 (HER2)-positive breast cancer depends largely on patients’ age and hormone receptor status, according to a review published in PLOS...
How cost effective trastuzumab is for human epidermal growth factor receptor 2 (HER2)-positive breast cancer depends largely on patients’ age and hormone receptor status, according to a review published in PLOS...
How...
09/06/2016
Journal of Clinical Pathways
Research in Review
Treatment Combination Improves NSCLC Survival and Response
08/12/2016
JCP Editors
East Asian patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and epidermal growth factor receptor mutations may benefit from treatment with pemetrexed plus gefitinib, results from a phase II...
East Asian patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and epidermal growth factor receptor mutations may benefit from treatment with pemetrexed plus gefitinib, results from a phase II...
East...
08/12/2016
Journal of Clinical Pathways
Research in Review
Ipilimumab Combination Significantly Improves Melanoma Outcomes
07/27/2016
JCP Editors
Ipilimumab (Yervoy; Bristol-Myers Squibb) combined with local peripheral treatments such as radiotherapy or electrochemotherapy may significantly prolong survival in patients with melanoma compared with...
Ipilimumab (Yervoy; Bristol-Myers Squibb) combined with local peripheral treatments such as radiotherapy or electrochemotherapy may significantly prolong survival in patients with melanoma compared with...
...
07/27/2016
Journal of Clinical Pathways
Research in Review
Cost-Effectiveness of Two NSCLC Treatments Compared
07/15/2016
JCP Editors
Compared with docetaxel, nivolumab is not a cost-effective treatment option for nonsquamous non-small cell lung cancer unless its price is reduced or it is used after programmed death ligand 1 (PD-L1) testing,...
Compared with docetaxel, nivolumab is not a cost-effective treatment option for nonsquamous non-small cell lung cancer unless its price is reduced or it is used after programmed death ligand 1 (PD-L1) testing,...
...
07/15/2016
Journal of Clinical Pathways
Interview
Immunotherapies and the Future of Cancer Care
03/08/2016
Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...
Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...
Five...
03/08/2016
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use